Unclaimed Scholar Profile
Are you Adrian David Marais? This profile has been curated from verified academic registries. Claim your profile to edit affiliations, manage works, and access your dashboard.
Verified ScholarVerified at University of Cape TownASIDASID-2938-0490-1969 orcid.org/0000-0001-5678-5714
Adrian David Marais
University of Cape Town•South Africa
Faculty researcher at University of Cape Town (ZA), specializing in Physical Sciences & Engineering. [Discipline: Physical Sciences & Engineering] [Scholar Type: Journal Research Scientist] [Career Tier: Distinguished Scholar] [Region: Southern Africa]
#Lipoproteins and Cardiovascular Health#Lipid metabolism and disorders#Cholesterol and Lipid Metabolism#Diabetes#Cardiovascular Risks#and Lipoproteins
Scholarly Profiles: Google Scholar
Citation Indices
Standard Scientometrics| All | Since 2021 | |
|---|---|---|
| Citations | 7,404 | 3,554 |
| h-index | 42 | 32 |
| i10-index | 97 | 68 |
Annual Citation Growth
Verified Citations / Year0
2020355
2021+40%498
2022+29%640
2023+33%853
2024-8%782
2025-46%426
2026Scholarship Distribution & Proportions161 Articles • 0 Books & Monographs • 0 Applied Assignments
Continental Provenance:82% African Regional Citations (6,071) • 18% Global Research Impact (1,333)
161 Indexed WorksAuthentic Data
Co-Authors & Academic Collaborators
No verified co-authors registered on AfriJournal Index yet.
Browse African Scholars →Scientific Bibliography Ingestion Notice
AfriJournal Index synchronizes authentic African citations and scholarship from Crossref, OpenAlex, and verified institutional repositories. Due to external indexing latency, some historical works may not yet be ingested in this snapshot. If you are this scholar, claim this profile to link your ORCID and verify your complete bibliography.
Articles & Books (161)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Published in The Lancet•2010
DOI: 10.1016/s0140-6736(10)60284-x Verified Peer-Reviewed
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
Published in The Lancet•2012
DOI: 10.1016/s0140-6736(12)61731-0 Verified Peer-Reviewed
Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease
Published in Pathology•2018
DOI: 10.1016/j.pathol.2018.11.002 Verified Peer-Reviewed
Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy
Published in Circulation•2011
DOI: 10.1161/circulationaha.111.042523 Verified Peer-Reviewed
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Published in Atherosclerosis•2006
DOI: 10.1016/j.atherosclerosis.2006.08.039 Verified Peer-Reviewed
Showing 1 – 5 of 161 publications
1 / 33